A Phase 2 interventional study of Adavosertib in Advanced Lymphoma, Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation. AZD1775 may block a protein called WEE1, which may be needed for growth of cancer cells that express BRCA mutations. Researchers hope to learn if AZD1775 will shrink this type of cancer or stop its growth.
PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
SECONDARY OBJECTIVES:
I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.
II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.
IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.
OUTLINE:
Patients receive adavosertib (AZD1775) orally (PO) once daily (QD) on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months if less than 2 years from study entry, and then every 6 months for an additional year from study entry.
THE MATCH SCREENING TRIAL:
Please see NCT02465060 for information on the MATCH Screening Protocol and applicable documents.
1,463 studies on the registry are indexed under Hematologic Neoplasms; 432 are open to participants now.
This study's enrollment of 33 is below the median of 45 across 1,068 interventional studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.
Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: Adavosertib
Given PO
Also known as: AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775
Objective Response Rate (ORR)
ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.
Time frame: Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
6-month Progression-Free Survival (PFS)
Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro- Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.
Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles, and every 4 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined
Progression-free Survival
PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.
Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Subprotocol Z1I was activated on March 13, 2017. Thirty-three patients were enrolled on EAY131-Z1I between March 24, 2017, and August 9, 2017.
| Milestone | Treatment (Adavosertib) |
|---|---|
| Started | 33 |
| Started protocol therapy | 33 |
| Eligible and treated | 30 |
| Completed | 0 |
| Not completed | 33 |
| Withdrew: Ineligible | 3 |
| Withdrew: Adverse event | 4 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 19 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Physician decision | 1 |
ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.
| percentage of participants | Treatment (Adavosertib) |
|---|---|
| Objective Response Rate (ORR) | 3.3 (0.2 to 14.9) |
Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro- Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.
| percentage of participants | Treatment (Adavosertib) |
|---|---|
| 6-month Progression-Free Survival (PFS) | 23.4 (10.7 to 36.2) |
PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.
| months | Treatment (Adavosertib) |
|---|---|
| Progression-free Survival | 2.0 (1.5 to 2.1) |
Collected over Assessed every 21 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment (Adavosertib) | 27/33 (81.8%) | 18/33 (54.5%) | 26/33 (78.8%) |
| Event | Treatment (Adavosertib) |
|---|---|
| Neutrophil count decreasedInvestigations | 7/33 |
| FatigueGeneral disorders | 4/33 |
| NauseaGastrointestinal disorders | 4/33 |
| Platelet count decreasedInvestigations | 4/33 |
| White blood cell decreasedInvestigations | 4/33 |
| HyperglycemiaMetabolism and nutrition disorders | 4/33 |
| AnemiaBlood and lymphatic system disorders | 3/33 |
| VomitingGastrointestinal disorders | 3/33 |
| HypophosphatemiaMetabolism and nutrition disorders | 3/33 |
| DiarrheaGastrointestinal disorders | 2/33 |
| Event | Treatment (Adavosertib) |
|---|---|
| FatigueGeneral disorders | 17/33 |
| DiarrheaGastrointestinal disorders | 15/33 |
| NauseaGastrointestinal disorders | 13/33 |
| AnemiaBlood and lymphatic system disorders | 12/33 |
| Aspartate aminotransferase increasedInvestigations | 8/33 |
| HypoalbuminemiaMetabolism and nutrition disorders | 8/33 |
| VomitingGastrointestinal disorders | 7/33 |
| Alkaline phosphatase increasedInvestigations | 7/33 |
| White blood cell decreasedInvestigations | 7/33 |
| HyperglycemiaMetabolism and nutrition disorders | 7/33 |
Patients who were eligible and started protocol therapy were the analyzable patients
| Age, Continuous(years) | Treatment (Adavosertib) |
|---|---|
| Median | 61.5 (36 to 79) |
| Sex: Female, Male(Participants) | Treatment (Adavosertib) |
|---|---|
| Female | 19 |
| Male | 11 |
| Ethnicity (NIH/OMB)(Participants) | Treatment (Adavosertib) |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 27 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Treatment (Adavosertib) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 23 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI)